X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
80
PharmaCompass offers a list of Canrenoate Potassium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Canrenoate Potassium manufacturer or Canrenoate Potassium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Canrenoate Potassium manufacturer or Canrenoate Potassium supplier.
PharmaCompass also assists you with knowing the Canrenoate Potassium API Price utilized in the formulation of products. Canrenoate Potassium API Price is not always fixed or binding as the Canrenoate Potassium Price is obtained through a variety of data sources. The Canrenoate Potassium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Canrenoate Potassium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Canrenoate Potassium, including repackagers and relabelers. The FDA regulates Canrenoate Potassium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Canrenoate Potassium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Canrenoate Potassium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Canrenoate Potassium supplier is an individual or a company that provides Canrenoate Potassium active pharmaceutical ingredient (API) or Canrenoate Potassium finished formulations upon request. The Canrenoate Potassium suppliers may include Canrenoate Potassium API manufacturers, exporters, distributors and traders.
click here to find a list of Canrenoate Potassium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Canrenoate Potassium Drug Master File in Japan (Canrenoate Potassium JDMF) empowers Canrenoate Potassium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Canrenoate Potassium JDMF during the approval evaluation for pharmaceutical products. At the time of Canrenoate Potassium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Canrenoate Potassium suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Canrenoate Potassium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Canrenoate Potassium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Canrenoate Potassium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Canrenoate Potassium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Canrenoate Potassium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Canrenoate Potassium suppliers with NDC on PharmaCompass.
Canrenoate Potassium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Canrenoate Potassium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Canrenoate Potassium GMP manufacturer or Canrenoate Potassium GMP API supplier for your needs.
A Canrenoate Potassium CoA (Certificate of Analysis) is a formal document that attests to Canrenoate Potassium's compliance with Canrenoate Potassium specifications and serves as a tool for batch-level quality control.
Canrenoate Potassium CoA mostly includes findings from lab analyses of a specific batch. For each Canrenoate Potassium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Canrenoate Potassium may be tested according to a variety of international standards, such as European Pharmacopoeia (Canrenoate Potassium EP), Canrenoate Potassium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Canrenoate Potassium USP).
Market Place
